Business Wire

Media-Telecom Convergence Projects Demo by IBC and TM Forum at Digital Transformation World

Jaa

TM Forum, the industry association driving digital transformation through collaboration, and IBC, the world’s most influential media, entertainment and technology show, unveiled the details of three joint proof-of-concept Catalyst projects to be demonstrated at Digital Transformation World in Nice, France, May 14-16, 2019.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190513005442/en/

Catalysts are proof-of-concept projects developed collaboratively. These projects bring together companies large and small to create innovate solutions to common challenges demonstrating how this can be achieved leveraging key TM Forum best practices and standards.

These three unique Media-Telecom Convergence Catalyst projects are the first results of IBC and TM Forum’s collaboration aimed at driving open innovation between the telecoms and media industries. Featured among the 32 projects demonstrated at Digital Transformation World, they incorporate some of today’s most complex business and technology challenges today, including 5G, data management, virtual and augmented reality, edge computing, AI and the automation of business processes for regulatory compliance.

The three Media-Telecom Catalysts are:

  • 5G-Enabled Tourism Experience
    This Catalyst explores ways of creating a pop-up network for delivery of high throughput broadcasting to distant points of fiber presence via mmWave connection. The project investigates how to deliver rich and engaging video-based experiences to users exploring an area of the Roman Baths in the UK and allows a mobile device to view a place as it would have been in the past. Champions: Aardman Entertainment, BBC R&D Participants: Bristol University, Cambridge Communications Systems Ltd., Zeetta Networks Ltd.
  • AI Indexing for Regulatory Practice
    This Catalyst is exploring ways to intelligently automate the identification of on-air content using AI in order to measure and report against compliance metrics set by external regulatory bodies, as well as for accurate measurement of internal editorial, creative and technical standards. Champions: Associated Press, Al Jazeera, RTE; Participants: Metaliquid, QCRI, Tech Mahindra, V-Nova
  • Mobile News Gathering Using AI-Powered Compression
    This Catalyst is working to empower newsrooms and journalists through improved intelligence for the mobile reporter in the field and faster time-to-air for both live and pre-recorded content. It leverages AI and techniques for improved bandwidth utilization through advanced compression techniques. Champions: Associated Press, Al Jazeera, RTE; Participant: V-Nova

“The convergence between telecom and media and entertainment has opened up exciting opportunities for our members to work alongside some of the world’s leading media companies to solve pressing business challenges,” said Andy Tiller, Executive Vice President, Collaboration and Innovation, TM Forum. “These three projects truly showcase how the power of collaboration helped find unique real-world solutions to problems faced by both industries – not only transforming businesses but consumer experience as well."

“As the pace of technology disruption and convergence accelerates, the rapid-fire Media-Telco Catalyst model for cross-sector innovation, partnerships and broader digital transformation is already proving a game-changing approach.” said Imran Sroya, Director, IBC. “We are delighted with the progress of the first three Catalyst projects and look forward to showcasing them at Digital Transformation World this month and at IBC in Amsterdam in September.”

Learn more about TM Forum’s Catalyst program at Digital Transformation World in Nice, France, May 14-16, 2019. With a focus on intelligent operations for a 5G world, Digital Transformation World showcases how businesses can seize opportunity and remain competitive in a rapidly evolving digital world. Click here for the latest event agenda: https://dtw.tmforum.org/agenda/

Ends

About TM Forum

TM Forum is an association of over 850-member companies’ customers across 180 countries. We drive collaboration and collective problem-solving to maximize the business success of communication and digital service providers and their ecosystem of suppliers around the world. Today, our focus is on supporting members as they navigate their unique digital transformation journeys, providing practical and proven assets and tools to accelerate execution and platforms to facilitate collaborative problem solving and innovation. Learn more at www.tmforum.org.

About IBC

IBC is the world’s most influential media, entertainment and technology show, attracting 55,000+ attendees from more than 170 countries and combining a highly respected and peer-reviewed conference with an exhibition that showcases 1,700+ leading industry suppliers of state-of-the-art technology. In addition to the world-class exhibition and conference, IBC also encompasses the IBC Daily, IBCTV and IBC365.

IBC365 provides year-round insight and opinion into the hot topics and key trends from leading industry journalists, along with insightful whitepapers, peer reviewed technical papers, highly engaging webinars and an expansive video library.

Contact information

CCgroup PR
Anais Merlin
E: TMForum@ccgrouppr.com
T: +44 203 824 9200

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

New Exploratory Data from VARSITY, First Head-to-Head Ulcerative Colitis Biologic Study Which Demonstrated Superiority of Vedolizumab to Adalimumab in Clinical Remission at Week 52, Presented at 2019 Digestive Disease Week®20.5.2019 03:16:00 EESTTiedote

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the Phase 3b head-to-head VARSITY study, which demonstrated that the gut-selective biologic vedolizumab (Entyvio®) was superior to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira®) in achieving clinical remission* at week 52 in patients with moderately to severely active ulcerative colitis (UC).1 New exploratory data showed that a greater proportion of patients receiving vedolizumab intravenous (IV) achieved clinical response** at week 14 compared to those treated with adalimumab subcutaneous (SC), 67.1% vs. 45.9% respectively. A separation between the treatment groups was seen as early as week 6, favoring vedolizumab. These results were announced in a Distinguished Abstract Plenary Lecture Presentation at the 2019 Digestive Disease Week® (DDW) annual scientific meeting (May 18-21 in San Diego, CA), one of 18 Takeda sponsored vedolizumab abstracts accep

Age, Gender, Disease Severity Impact Adherence to Long-Term PAP Therapy More Than Previously Thought19.5.2019 22:15:00 EESTTiedote

ResMed (NYSE: RMD, ASX: RMD) today revealed several demographic and clinical factors affect adherence to PAP (positive airway pressure) therapy, according to a study it presented at the American Thoracic Society's ATS 2019 International Conference. The study found significant differences in one-year adherence between people of different ages and disease severity levels: Men with sleep apnea are 8.5 percentage points more likely to stay adherent on PAP therapy than women. People over age 60 were 7.3 percentage points more adherent than the entire study cohort (77.7% vs. 70.4%). People with self-reported severe sleep apnea were 78% adherent at the one-year mark, compared to 70.5% of those with self-reported moderate sleep apnea, and 65.2% of those with mild sleep apnea. “Sleep specialists, pulmonologists, and primary care physicians should heed these results and ensure that their younger, female, and more mildly diagnosed patients have the proper supports to stay on therapy,” said Adam B

Workiva Named Best-In-Class Cloud Service Provider at UK Cloud Awards17.5.2019 15:00:00 EESTTiedote

Workiva (NYSE:WK), the leading cloud provider of connected data, reporting and compliance solutions, was named the Best-In-Class Cloud Service Provider by the UK Cloud Awards 2019 at a ceremony here last night. Now in its sixth year, the UK Cloud Awards recognise innovation and excellence in the cloud industry by showcasing leading companies, customers and individuals in the United Kingdom. Workiva was recognised for its Wdesk platform that helps organisations consolidate, connect and tag their data in a single, cloud environment so they are able to reduce risk and save time when filing reports with various regulators and other stakeholders. Workiva, the global leader in XBRL and Inline XBRL, is also streamlining how customers comply with the European Securities and Markets Authority's mandate for Inline XBRL for European Single Electronic Format (ESEF) reporting. More than 5,000 EU issuers will be required to use ESEF taxonomy for their annual financial reports, ending on or after Jan

Novaremed Presents Top-Line Results from Phase 2a Diabetic Neuropathic Pain Study of NRD.E1 at NeuPSIG 201917.5.2019 13:13:00 EESTTiedote

Novaremed AG, a clinical-stage Swiss biopharmaceutical company, today announced a poster presentation highlighting the top-line results from a Phase 2a (Proof of Concept) study of NRD.E1 for the treatment of diabetic neuropathic pain (DNP). The poster presentation took place at the 7th International Congress on Neuropathic Pain Meeting (NeuPSIG) in London, UK on May 9-11, 2019. “This was our first communication at a leading neuropathic pain-focused event. Novaremed’s lead drug, NRD.E1 is a non-opioid small molecule for the treatment of neuropathic pain. The results of our Phase 2a in patients with DNP showed clinically relevant treatment benefit from NRD.E1 across multiple primary and secondary endpoints, providing a strong scientific foundation for advancing the development of NRD.E1 into the upcoming global Phase 2b study in DNP,” said Sara Mangialaio, Head of R&D and Chief Medical Officer of Novaremed AG. “NRD.E1 has the potential to address a major unmet medical need in DNP.” Poste

WIN 2019 Symposium: WINnovation and Global Deployment of Precision Oncology17.5.2019 12:38:00 EESTTiedote

The 11th WIN Symposium in Precision Oncology will be held in Paris, France on June 23-24, 2019. ASCO® endorsed for the past 11 years, the WIN symposium will deliver an exciting line-up of speakers in Paris (France) on June 23-24, 2019 to discuss Innovation and Global Deployment of Precision Oncology. The current status of Precision Oncology across the globe will be examined with the exceptional participation of the chairmen of the event, Richard L. Schilsky, Chairman WIN Consortium(*), Senior Vice-President and Chief Medical Officer of ASCO, and Josep Tabernero, Vice Chairman WIN Consortium, President of ESMO and Director of Vall d’Hebron Institute of Oncology, Spain. Global experience will be shared: Optimizing Patient Enrollment and Efficacy of Precision Oncology Clinical Trials at UT MD Anderson Cancer Center, USA Decision Support for Precision Oncology: Evolving from Monotherapy to Genomically Informed Combinations, UT MD Anderson Cancer Center, USA The Value of Personalized Medici

Corsearch Acquires Principium Trademark Watch and Domain Services Businesses17.5.2019 11:00:00 EESTTiedote

Corsearch, the global brand creation, clearance, and protection leader, is pleased to announce the acquisition of the Principium Strategies trademark watch and domain services businesses, the brand protection subsidiary of Ladas and Parry LLP, a leader in global intellectual property law. The acquisition is effective immediately, solidifying and expanding Corsearch’s full-service trademark solutions offering for clients and brands globally. Principium is Corsearch’s third acquisition since becoming a standalone company in January 2018. The acquisition brings Corsearch’s employee count to more than 350 operating in 28 locations worldwide and adds valuable industry expertise and additional capabilities to Corsearch. “This is another really exciting acquisition for our business and a step forward in the evolution of Corsearch,” said Stephen Stolfi, Chief Commercial Officer of Corsearch. “Principium has provided clients with industry-leading trademark watching services for over 80 years an

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme